SF3B1 mutation analysis-994

Test info

  
SF3B1 mutation analysis
  
994
  
LAB994
  
MSO
  
SF3B1 gene sequencing

Specimen

  
EDTA whole blood
  
  
5 mL
  
2 mL
  

Immediately following collection, mix by inverting 8 - 10 times to prevent clotting

  

Lavender (EDTA), 4mL

  
EDTA bone marrow
  

Lavender (EDTA), 4mL

  

Refrigerated - <72 hours

Ship same day if possible

Performance

  
NeoGenomics
  
Varies
  
10 days
  

RT-PCR and bi-directional sequencing of exons 14-17 of the SF3B1 gene

Clinical and Interpretive info

  

An interpretive report will be provided

  

SF3B1 mutations occur in 10-15% of CLL patients and serve as independent predictors of shortened time to treatment and poorer overall survival in CLL. Mutations are also detected in approximately 28% of MDS and 19% of myelodysplastic/myeloproliferative neoplasms. In MDS/MPN, most mutations were found in refractory anemia with ring sideroblasts (the RARS subtype).

Billing

  
This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection
  
81479
  
Yes
  

Tracking

  
07/15/2019
  
06/23/2023